Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMycelx Di Regulatory News (MYX)

Share Price Information for Mycelx Di (MYX)

Share Price is delayed by 15 minutes
Get Live Data
64.00    2.00 (3.23%)
Bid:
63.00
Ask:
65.00
Spread: 2.00 (3.175%)
Market Cap: £15.59m
MYX Live PriceLast checked at - London Stock Exchange

Intraday Mycelx Di Share Chart

Trading Update

23 Sep 2024 07:00

RNS Number : 2035F
MyCelx Technologies Corporation
23 September 2024
 

The information contained within this Announcement is deemed by MYCELX Technologies Corporation to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR").

 

23 September 2024

MYCELX Technologies Corporation

("MYCELX" or the "Company")

Trading Update

MYCELX Technologies Corporation (AIM: MYX), the clean water and clean air technology company, announces a trading update following changes to the customer's project timeline at one of its REGEN installations for a customer in Nigeria.

 

As set out in the announcement dated 23 August 2024, the Company highlighted that the outturn for the current financial year would be dependent on projects meeting delivery timelines with one significant project in particular expecting to be recognised in December when factory acceptance testing was due to be completed.

 

Subsequent to successful achievement of the last project milestone three weeks ago for the above-mentioned project, the Company has just recently been made aware by the customer that the next major milestone has been delayed for several weeks. While not unusual for a project of this size and complexity, this delay comes at a critical time in terms of MYCELX's ability to deliver its equipment as scheduled. The Board recognises that there is now a strong possibility this delay will affect the Company's factory acceptance testing in mid-December, and revenue recognition in 2024, and as a result, the Board has made the prudent decision to shift anticipated revenue from the project from Q4 2024 to Q1 2025. The Company has accordingly revised its 2024 revenue forecast of $9.5 million to $4.5-$5.0 million and will recognise the project value of $5.4 million in 2025.

 

There will be no loss of revenue for the Company and minimal impact to the forecasted year end cash balance given MYCELX will continue to receive milestone payments that keep the project cash flow positive despite the delay. The Company will be announcing its Interim Results in the coming days.

 

The Company looks forward to working closely with its partners in Nigeria to successfully deliver this project and continuing its momentum in REGEN adoption in the oil and gas market.

 

Connie Mixon, CEO, commented:

 

"While this project will be marginally delayed, there will be no significant effect on the business since revenue is simply shifting from Q4 2024 to Q1 2025 and impact to the Company's cash balance at year end is minimal. We look forward to completion of this project which is our fourth installation in Nigeria where our technology is enabling producers to achieve their goals of better water treatment and a cleaner environment.

 

We plan to announce our Interim Results over the coming days, which will give the market further insight into the progress across our core markets."

 

For further information, please contact:

MYCELX Technologies Corporation

Connie Mixon, CEO

Kim Slayton, CFO

 

 

 

Tel: +1 888 306 6843

Canaccord Genuity Limited (Nominated Adviser and Sole Broker)

Henry Fitzgerald-O'Connor

Charlie Hammond

 

 

Tel: +44 20 7523 8000

Celicourt Communications (Financial PR)

Mark Antelme

Jimmy Lea

Charlie Denley-Myerson

 

 

Tel: +44 20 7770 6424

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTQKNBBPBKKNCB
Date   Source Headline
27th Jul 20187:00 amRNSContract Extension in Saudi Arabia
11th Jul 20181:16 pmRNSResult of Annual Meeting
7th Jun 20184:23 pmRNSBlock listing Interim Review
7th Jun 20183:42 pmRNSAnnual Financial Report
15th May 20187:00 amRNSFinal Results for the year ending 31 December 2017
19th Apr 20187:00 amRNSNew Purchase Order Award and Equipment Sale
13th Apr 201810:18 amRNSIssue of Equity
10th Apr 20187:00 amRNSPurchase Order Award & General Manager Appointment
28th Mar 201812:48 pmRNSHolding(s) in Company
16th Feb 20187:00 amRNSIssue of Equity
6th Feb 20187:00 amRNSExtension of Contract and New Project
17th Jan 20187:00 amRNSTrading Update
7th Dec 20179:46 amRNSBlock listing Interim Review
3rd Nov 201712:39 pmRNSIssue of Equity
26th Oct 20177:30 amRNSHolding(s) in Company
9th Oct 20177:00 amRNSIssue of Equity
27th Sep 20172:44 pmRNSApplication for Block Admission
26th Sep 20175:31 pmRNSClosure of Restricted Stock Line
21st Sep 20177:00 amRNSConsolidation of Stock Lines
13th Sep 20177:00 amRNSHalf Year Results Statement
12th Jul 201712:30 pmRNSResult of Annual Meeting
7th Jul 20177:00 amRNSHalf Year Trading Update
9th Jun 201710:00 amRNSMailing of Annual Financial Report & GM Notice
7th Jun 201710:30 amRNSBlock listing Interim Review
30th May 20171:19 pmRNSDirector/PDMR Shareholding
26th May 20177:00 amRNSContract win with new SABIC affiliate customer
11th May 20177:00 amRNSFinal Results for the year ending 31 December 2016
8th May 20177:00 amRNSContract Award & Notification of Full Year Results
30th Jan 20177:00 amRNSTrading Update
7th Dec 20162:34 pmRNSBlock listing Interim Review
4th Oct 20167:00 amRNSAppointment of Nominated Adviser & Broker
14th Sep 20167:00 amRNSHalf Year Results Statement
13th Jul 20164:21 pmRNSResult of AGM
11th Jul 20167:00 amRNSHalf Year Trading Update
30th Jun 20167:00 amRNSHolding(s) in Company
24th Jun 20167:00 amRNSMyCelx and Schlumberger Sign Upstream Agreement
9th Jun 20167:00 amRNSMailing of 2015 Annual Report and Notice of AGM
7th Jun 20163:32 pmRNSBlock listing Interim Review
17th May 20167:00 amRNSFinal Results
16th Mar 20167:00 amRNSAppointment of CFO/Grant of Share Options
4th Mar 20161:25 pmRNSHolding(s) in Company
4th Mar 20167:00 amRNSTrading Update
11th Jan 20165:30 pmRNSHolding(s) in Company
29th Dec 20152:23 pmRNSHolding(s) in Company
18th Dec 201510:13 amRNSHolding(s) in Company
15th Dec 20155:25 pmRNSHolding(s) in Company
15th Dec 20155:24 pmRNSHolding(s) in Company
11th Dec 20157:00 amRNSTrading Update
3rd Dec 201511:33 amRNSBlocklisting Interim Review
1st Oct 20157:00 amRNSProgress Update on Trials

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.